Xiang-Yu Han

Xiang-Yu Han

Auto-generated profile, based on publicly available information

Xiang-Yu Han

Renal Division, Department of Medicine, Peking University First Hospital; Peking University Institute of Nephrology; Beijing 100034, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XHXiang-Yu Han
Xiang-Yu Han
HQHui-Ru Qi
Hui-Ru Qi
Kawasaki disease (KD) is a relatively common autoimmune disease of childhood, characterized by systemic vasculitis and involvement of the cardiovascular system, particularly the coronary artery. Progressive inflammatory cascades and vascular injury are regarded as two major processes underlying KD. Although it is regarded as a self-limiting disease, some children exhibit resistance to intravenous immunoglobulin (IVIG) treatment, which can lead to the development of life-threatening coronary artery aneurysms that persist into adulthood. Pyroptosis, a special inflammatory cell death pattern, results in the intense release of inflammatory mediators and injuries of tissues such as endothelial cell damage. Evidence from in vitro studies and animal models suggests that pyroptosis and associated inflammatory cascades may play a significant role in KD. Here, we highlight the latest insights into pyroptosis in KD and explore the potential therapeutic interventions that target pyroptosis.

16 October 2025 in Apoptosis
Verified
Journal Article
Open access
PDF file
XHXiang-Yu Han
Xiang-Yu Han
YZyiyang zhao
yiyang zhao
SCSu-Fang Chen
Su-Fang Chen
ZLZhi-Ying Li
Zhi-Ying Li
MZMing-Hui Zhao
Ming-Hui Zhao
MCMin Chen
Min Chen
Neutrophil-mediated inflammation plays a crucial role in the pathogenesis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Dysregulated neutrophil death has been implicated in promoting neutrophil priming and activation. PANoptosis, an inflammatory programmed cell death, participates in the development of various autoimmune diseases. The current study aims to identify the key PANoptosis-related marker and investigate its association with disease activity of AAV. Gene microarray data of patients with ANCA-associated glomerulonephritis (ANCA-GN) was downloaded from the Gene Expression Omnibus (GEO). PANoptosis-associated genes were sourced from GeneCards. The hub-marker of PANoptosis-related genes was identified by integrated bioinformatical analysis. The single-cell sequencing data from ANCA-GN mice were used to determine the location of hub genes. Then levels of activated CD11b on neutrophils from peripheral blood, as well as soluble CD11b in urine and plasma were measured in AAV patients. Their associations with clinicopathological parameters of AAV patients were subsequently analyzed. Co-localization of CD11b and neutrophils in renal specimens of AAV patients was evaluated by immunofluorescence staining. Changes of intracellular metabolic pathways of neutrophils from AAV patients were further investigated. A small molecule inhibitor was used to explore the effect of intracellular fatty acid metabolism (FAO) on neutrophil CD11b activation and PANoptosis. CD11B was identified as the pivotal PANoptosis-related gene in AAV by integrated bioinformatics analysis. The level of activated CD11b on neutrophils was significantly higher in active AAV patients compared with healthy controls, and elevated neutrophil CD11b levels positively correlated with disease activity, as evidenced by higher levels of hypersensitive C-reactive protein (hCRP), increased Birmingham Vasculitis Activity Score (BVAS), elevated serum creatinine levels at sampling and a higher proportion of cellular crescents in renal specimens of AAV patients. We also demonstrated the presence of neutrophil CD11b in renal specimen of AAV patients. Moreover, along with elevated Cd11b expression, neutrophils from ANCA-GN mice exhibited an aberrant FAO phenotype and a down-regulated peroxisome proliferators-activated receptor (PPAR)-α pathway, as compared with healthy controls. GW7647, a PPARα agonist, could alleviate AAV serum-induced neutrophil CD11b activation and PANoptosis. CD11B was a pivotal PANoptosis-related gene in AAV. The level of activated CD11b on neutrophils was associated with disease activity in AAV patients.

1 January 2026 in RMD Open
Verified
Journal Article
Open access
XHXiang-Yu Han
Xiang-Yu Han
ZLZhi-Ying Li
Zhi-Ying Li
SCSu-Fang Chen
Su-Fang Chen
MZMing-Hui Zhao
Ming-Hui Zhao
MLMark A Little
Mark A Little
MCMin Chen
Min Chen
Objective: Postmarketing safety data of avacopan, the first Food and Drug Administration (FDA) approved drug in a decade for antineutrophil cytoplasmic antibody-associated vasculitis (AAV), are currently limited. This study aims to conduct a comprehensive real-world evaluation of its adverse events (AEs). Methods: The FDA Adverse Event Reporting System was comprehensively reviewed and analysed. Disproportionality analysis was conducted to evaluate the significance of avacopan-related AEs at both system organ class (SOC) and preferred terms (PTs) levels. Time-to-onset (TTO), Weibull shape parameter (WSP) analysis and cumulative incidence analyses were performed to explore the temporal patterns of AE occurrence. Additionally, subgroup analyses based on gender and age were undertaken. Results: A total of 3150 reports of avacopan-related AEs were identified. 8 positive SOC signals and 92 positive PT signals were detected, including 34 previously unrecognised PTs. None was classified as a high clinical priority. The median TTO was 48 days. Overall WSP analyses suggested an early failure type pattern, while event-specific analyses demonstrated heterogeneous temporal patterns. Patients aged≥65 years had a higher cumulative incidence of AEs. Hepatobiliary events were the leading ones, with a predominance of reports involving female and geriatric (≥65 years) patients. Conclusion: Avacopan demonstrated a favourable safety profile in patients with AAV in real-world settings. The overall AE risk increased with age, while hepatobiliary events were particularly more frequent among geriatric and female patients. Our study uncovered previously unrecognised AEs as well. These findings highlighted the need for risk-informed and AE-specific monitoring strategies to support individualised management.

6 November 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
XHXiang-Yu Han
Xiang-Yu Han
HQHui-Ru Qi
Hui-Ru Qi

26 May 2026 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
XHXiang-Yu Han
Xiang-Yu Han
ZLZhi-Ying Li
Zhi-Ying Li
SCSu-Fang Chen
Su-Fang Chen
MZMing-Hui Zhao
Ming-Hui Zhao
MLMark A Little
Mark A Little
MCMin Chen
Min Chen
Key Points: Canagliflozin ameliorated experimental ANCA-associated vasculitis through broad suppression of pathogenic T-cell subsets. The immunomodulatory effect of canagliflozin was mediated in part by inhibition of p38 mitogen-activated protein kinase signaling in T cells. Background: The nephroprotective role of sodium-glucose cotransporter 2 (SGLT2) inhibitors has been well established by several randomized controlled trials involving patients with diabetic and nondiabetic CKD. However, the impact of SGLT2 inhibitors on ANCA-associated vasculitis (AAV) and the underlying mechanisms remain unclear. Methods: The therapeutic effects of canagliflozin were evaluated in a rat model of experimental AAV. RNA sequencing was performed on the kidney and lymph nodes. In parallel, mechanistic studies were conducted in mouse models. Myeloperoxidase-deficient ( Mpo −/− ) mice were immunized with mouse myeloperoxidase and treated with canagliflozin. Splenocytes from these donors were then adoptively transferred into recombinase-activating gene-1–deficient ( Rag1 −/− ) mice. Comprehensive immune phenotyping by flow cytometry, enzyme-linked immunospot assays, and in vitro differentiation of human T cells were employed to dissect the immunomodulatory effects and underlying mechanisms. Results: Canagliflozin alleviated kidney injury, pulmonary hemorrhage, and T-lymphocyte infiltration in AAV rats. Renal transcriptomic analysis showed a suppression of adaptive immunity pathways. In the adoptive transfer model, canagliflozin treatment of donor mice led to a significant reduction in splenic Th1, Th17, and CD8 + T cells, accompanied by a markedly diminished capacity of splenocytes to secrete IFN- γ and IL-17A upon restimulation. Transfer of these modulated splenocytes conferred significant nephroprotection to recipient mice. In vitro , canagliflozin suppressed the differentiation of primary CD4 + T cells from patients with AAV into both Th1 and Th17 lineages, but did not directly affect B-cell activation or antibody production. Mechanistically, canagliflozin inhibited the phosphorylation of both p38 and extracellular signal-regulated kinase mitogen-activated protein kinases in activated T cells, and the suppressive effect on cytokine production was partially reversed by activation of the p38 mitogen-activated protein kinase pathway. Conclusions: Canagliflozin alleviated experimental AAV by suppressing pathogenic T cell effector responses—an effect mechanistically linked to inhibition of the p38 signaling pathway.

20 November 2024 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
XHXiang-Yu Han
Xiang-Yu Han